Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography

Authors
Jens Vogel-Claussen, Florian Lasch, Benjamin-Alexander Bollmann, Katharina May, Alexander Kuhlmann, Gerald Schmid-Bindert, Rudolf Kaaks, Jörg Barkhausen, Sabine Bohnet, Martin Reck
Journal
Chest
Related Product

LCS

Date Published
2022.08
Summary

The HANSE study, led by Jens Vogel-Claussen and colleagues, explores the potential of a national lung cancer screening program in Germany using Low-Dose Computed Tomography (LDCT). Aiming to reduce lung cancer mortality, the study targets high-risk individuals, defined using the NELSON and PLCOM2012 risk models. It compares the effectiveness of these models in detecting early-stage lung cancer and investigates the value of adding coronary calcium and emphysema scoring to LDCT reports. Over 5,000 high-risk participants are screened, with 7,100 low-risk individuals serving as controls. The study uses a modified Lung-RADS 1.1 system for lung nodule analysis and monitors patients for up to 10 years. Findings highlight LDCT’s potential not only in cancer detection but also in identifying risks for cardiovascular diseases, which could prompt preventive measures. Aview’s advanced technology aids in managing lung nodule data, contributing to the accuracy and comprehensiveness of the screening process.

Contact

Please leave your inquiry if you have any questions regarding our products, recruitment, investment, or any other matters.

Contact us